Investing.com - Arrowhead Pharma (NASDAQ: ARWR) reported fourth quarter EPS of $-1.36, $0.39 worse than the analyst estimate of $-0.97. Revenue for the quarter came in at $35M versus the consensus estimate of $55.07M.
Arrowhead Pharma's stock price closed at $21.05. It is down -11.67% in the last 3 months and down -27.21% in the last 12 months.
Arrowhead Pharma saw 0 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Arrowhead Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Arrowhead Pharma's Financial Health score is "weak performance".
Check out Arrowhead Pharma's recent earnings performance, and Arrowhead Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar